Showing results (441-450 of 494) with videos related to
Sort By:
Pageof 50
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.Lancet (London, England)|April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJason J Luke, Piotr Rutkowski, Paola Queirolo, et al.The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.European Journal of Cancer (Oxford, England : 1990)|June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective studyMario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.Lancet (London, England)|June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialHans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.Pageof 50